Linked Life Data

2990711

Source:http://linkedlifedata.com/resource/pubmed/id/2990711

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7-8
pubmed:dateCreated
1985-9-19
pubmed:abstractText
A prospectively randomized, double-blind clinical trial was conducted to evaluate the effect of immunotherapy with transfer factor (TF) as an adjunct to radiotherapy of patients with stage III nasopharyngeal carcinoma (NPC). The TF was derived from normal young adults with a proven history of infectious mononucleosis and from normal blood donors with elevated antiviral capsid antigen antibody activity. TF prepared in this fashion was previously shown to convert the leukocytes of patients with NPC to a reactive state in vitro and when administered to NPC patients in vivo was associated with apparent slowing of tumor growth, marked lymphocytic infiltration of the tumor, and reconstitution of delayed cutaneous hypersensitivity reactions. From 1974 to 1977, 100 patients with NPC were entered in the study; one-half of the patients were treated with radiotherapy alone and one-half received radiotherapy and an 18-month course of TF immunotherapy. The patients were followed for at least 5 years. No significant difference in disease-free survival or survival was noted between the two groups of patients. The use of this particular preparation and dose schedule of TF in patients with NPC with regional disease was devoid of any anti-tumor activity.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0361-5960
pubmed:author
pubmed:issnType
Print
pubmed:volume
69
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
761-7
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:articleTitle
Cooperative trial of immunotherapy for nasopharyngeal carcinoma with transfer factor from donors with Epstein-Barr virus antibody activity.
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial, Research Support, Non-U.S. Gov't